Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Drug Resistant Epilepsy × Sirolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 36 Leukemia, Myeloid, Acute 32 Myelodysplastic Syndromes 29 Lymphoma, Non-Hodgkin 26 Hodgkin Disease 26 Multiple Myeloma 25 Leukemia, Lymphocytic, Chronic, B-Cell 24 Lymphoma 23 Leukemia 23 Graft vs Host Disease 22 Hematologic Neoplasms 19 Lymphoma, Mantle-Cell 17 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 16 Sarcoma 15 Neoplasms 15 Myeloproliferative Disorders 14 Lymphoma, Large B-Cell, Diffuse 14 Burkitt Lymphoma 14 Tuberous Sclerosis 13 Breast Neoplasms 13 Recurrence 12 Lymphoma, Follicular 12 Waldenstrom Macroglobulinemia 11 Primary Myelofibrosis 11 Neoplasm Metastasis 11 Lymphoma, B-Cell, Marginal Zone 11 Leukemia, Myelomonocytic, Chronic 11 Neoplasms, Plasma Cell 10 Leukemia, Myeloid, Chronic-Phase 10 Leukemia, Myeloid, Accelerated Phase 10

Interventions

perampanel 1 Sirolimus 1 Immunoglobulins, Intravenous 1 Diet, Ketogenic 1 Cannabidiol 1 Anticonvulsants 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05534672 2023-08-08

RaRE-TS

Children's Memorial Health Institute, Poland

Phase 3 Recruiting

Drug Resistant Epilepsy, Epilepsy, Tuberous Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡